Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad Laboratories Inc. reports fourth-quarter results Thursday after market close, with investors looking to see whether the life sciences tools maker can sustain momentum from a strong prior ...

Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the ...

Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I would like to hand things over to Mr. Edward Chung. Please go ahead, sir. Good ...

(RTTNews) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025. The company posted ...

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a micro-cap diagnostics company with a market capitalization of just under $15 million, announced Tuesday that its Premier Hb9210 HbA1c Analyser with ...

The TC20 automated cell counter counts mammalian cells in one simple step using its innovative auto-focus technology and sophisticated cell counting algorithm to produce accurate cell counts in less ...

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to ...